Table 1: Baseline characteristics of the participants.

VPZ group ()PPI group () value
VPZ versus PPI
RPZ group () value
VPZ versus RPZ

Age (yrs)58 (32–80)60 (36–77)0.719661 (36–77)0.9299
Male41/72 (57%)40/69 (58%)0.901935/59 (59%)0.7838
Body mass index (kg/m2)22.4 (17.9–30.7)22.6 (16.1–37.8)0.478022.7 (16.1–37.8)0.3382
Smoking17/70 (24%)19/67 (28%)0.588315/57 (26%)0.7932
Drinking22/72 (31%)22/67 (33%)0.772718/57 (32%)0.9007
Comorbidities
 Gastric ulcer1/72 (1.4%)1/69 (1.4%)1.00001/59 (1.7%)1.0000
 Duodenal ulcer2/72 (2.8%)2/69 (2.9%)1.00002/59 (3.4%)1.0000
 Diabetes8/72 (11.1%)2/69 (2.9%)0.09762/59 (3.4%)0.1838
 Hypertension14/72 (19.4%)17/69 (24.6%)0.456716/59 (27.1%)0.2983
 Hyperlipidemia8/72 (11.1%)14/69 (20.3%)0.133314/59 (23.7%)0.0546
AST (IU/L)20 21 0.742421 0.3131
ALT (IU/L)17 17 0.411417 0.1291
Creatinine (mg/dL)0.78 0.78 0.63560.78 0.3345
Hemoglobin A1c (%)5.6 5.6 0.13005.6 0.3101

Data are expressed as median (range) or number (percentage). Statistical analyses were conducted with the Mann–Whitney U test and chi-square test or Fisher’s exact test. VPZ group, treatment with vonoprazan, amoxicillin, and clarithromycin; PPI group, treatment with rabeprazole or lansoprazole, amoxicillin, and clarithromycin; RPZ group, treatment with rabeprazole, amoxicillin, and clarithromycin; AST, aspartate aminotransferase; ALT, alanine aminotransferase. , , , , , and .